四川省成都市东御街 18 号百扬大厦 1 栋 11 楼邮编：610000 网址/WEBSITE：www.kangdacdlawyers.com 北京康达（成都）律师事务所 关 于 四川路桥建设集团股份有限公司 解除限售条件成就以及回购注销部分限制性股票的 法律意见书 康达（成都）法意字2025第 0372 号 二〇二五年六月 北京 BEIJING 上海 SHANGHAI 广州 GUANGZHOU 深圳 SHENZHEN 海口 HAIKOU 西安 XI'AN 天津 TIANJIN 杭州 HANGZHOU 南京 NANJING 沈阳 SHENYANG 成都 CHENGDU 菏泽 HEZE 苏州 SUZHOU 武汉 WUHAN 香港 HONGKONG 呼和浩特 HUHEHAOTE 1 厦门 XIAMEN 长沙 CHANGSHA 重庆 CHONGQING 郑州 ZHENGZHOU 合肥 HEFEI 宁波 NINGBO 济南 JINAN 昆明 KUNMING 南昌 NANCHANG 法律意见书 目 录 | 法律意见书 | | | --- | --- | | 释 | 义 | | 在本《法律意见书》中，除非文义另有所指，下 ...

序号 姓名 职务 科沃斯机器人股份有限公司董事会 科沃斯机器人股份有限公司 （预留授予日） 一、股票期权激励计划预留部分的分配情况 获授的股票期 占预留授予股 占预留授予 序号 姓名 职务 权数量 票期权总数的 公告日股本 （万份） 比例 总额的比例 中层管理人员、核心技术（业务）人 员以及公司其他骨干员工（506 人） 总计 339.76 100.00% 0.59% 注：1、上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票 累计未超过本激励计划草案公告时公司股本总额的 1%。公司全部在有效期内的股权激励计 划所涉及的标的股票总数累计未超过本激励计划草案公告时公司股本总额的 10%。 司 5%以上股份的股东或实际控制人及其配偶、父母、子女。 二、其他激励对象名单 序号 姓名 职务 三、限制性股票激励计划预留部分的分配情况 获授的限制性 占预留授予限 占预留授予 序号 姓名 职务 股票数量 制性股票总数 公告日股本 （万股） 的比例 总额的比例 中层管理人员、核心技术（业务）人 员以及公司其他骨干员工（483 人） 总计 155.81 100.00% 0.27% 注：1、上述任何一名激励对象 ...

关于欧菲光集团股份有限公司 限制性股票第一个解除限售期解除限售条件成就及 回购注销部分限制性股票事项 的法律意见书 中国 深圳 福田区 益田路 6001 号太平金融大厦 11、12 楼 邮政编码：518038 电话(Tel.)：(0755) 8826 5288 传真(Fax.)：(0755) 8826 5537 网址（Website）：www.sundiallawfirm.com 法律意见书 广东信达律师事务所 关于欧菲光集团股份有限公司 第一个解除限售期解除限售条件成就及回购注销部分限制性股票事 项的法律意见书 信达励字（2025）第083号 致：欧菲光集团股份有限公司 广东信达律师事务所（以下简称"信达"）接受欧菲光集团股份有限公司（以 下简称"欧菲光"或"公司"）的委托，担任公司本次实行 2024 年第一期限制 性股票与股票期权激励计划（以下简称"本股权激励计划""本计划""本激励 计划"）的专项法律顾问。信达根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司股权激励管理办法》（以下简称"《管理办法》"）等有关法律、法规和规 范性文 ...

Group 1 - The company has announced a restricted stock incentive plan for 2025, granting 5 million shares at a price of 95 yuan per share to 1,368 individuals, representing 0.61% of the total share capital at the time of the announcement [2] - The incentive plan's assessment period is set from 2025 to 2027, with revenue growth targets of 20.00%, 44.00%, and 72.80% for the respective years, based on the 2024 revenue as a baseline [3] - The expected amortization expenses for the stock incentive plan from 2025 to 2028 are projected to be 57.34 million, 87.30 million, 44.76 million, and 14.80 million yuan respectively [3] Group 2 - The company has invested 2.261 billion yuan in R&D in 2024, accounting for 21.95% of its revenue, indicating a strong commitment to innovation [4] - The company has launched several strategic innovative products, including the uLinacHalosTx precision radiotherapy system and the uMR Max 3.0T MRI, which are expected to enhance its competitive position [4] - The domestic medical imaging equipment bidding market is projected to grow by 100.36% year-on-year from January to May 2025, suggesting a potential improvement in the company's performance as the market recovers [4]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The recent stock incentive plan reflects the company's confidence in long-term development, with a target revenue growth rate of 20.00%/44.00%/72.80% for 2025-2027 [2] - The company continues to invest heavily in R&D, with an expected investment of 2.261 billion yuan in 2024, accounting for 21.95% of revenue [3] - The medical imaging equipment bidding market is expected to recover, which will significantly improve the company's performance [3] Summary by Sections Investment Rating - The company is rated as "Buy" based on its strong market position and growth potential [5] Stock Incentive Plan - The company announced a stock incentive plan for 1,368 employees, granting 5 million shares at 95 yuan per share, representing 0.61% of the total share capital [1] - The assessment period for the stock incentive is set for 2025-2027, with specific revenue growth targets and trigger values for each year [2] R&D and Product Development - The company has launched several innovative products, including the uLinacHalosTx precision radiotherapy system and the uMR Max 3.0T MRI [3] - The R&D investment is projected to continue to support the company's competitive edge in the medical imaging sector [3] Financial Forecasts - The company is projected to achieve net profits of 1.966 billion yuan, 2.281 billion yuan, and 2.817 billion yuan for 2025, 2026, and 2027 respectively [3] - Revenue is expected to grow from 11.863 billion yuan in 2025 to 17.390 billion yuan in 2027, with corresponding growth rates of 15.17%, 20.43%, and 21.73% [4]

积极推动股权激励计划，保障核心团队稳定，促进公司长远发展。为了进一步建立、健全公司长效激励 与约束机制，吸引和留住优秀人才，扩大激励对象覆盖面，强化激励效果，促进公司长期稳定发展，在 充分保障股东利益的前提下，公司计划向公司董事、高级管理人员及核心骨干员工合计252 人授予股权 激励，股权激励规模为1,000 万股，占总股本的1.47%。计划以2022-2024 年营收均值为基数，设定2025- 2027 年营收增长目标分别为34%、40%、46%。高增长目标不仅彰显管理层对公司未来发展的信心，也 通过阶梯式业绩考核形成良性机制，推动公司经营状况持续稳定增长。 盈利预测与投资建议：预计公司2025/2026/2027年实现营业收入分别为33.0/37.9/42.7亿元，同比增长 19.4%/14.9%/12.9%；实现归属上市公司股东的净利润分别为2.97/3.55/3.82 亿元， 同比增长 51.9%/19.4%/7.7%，对应2025/2026/2027年的PE分别为26.2/22.0/20.4倍，同类可比公司三安光电/兆驰股 份/乾照光电现价对应2025年的PE估值分别为48.4/10.0/66.1倍 ...

Core Viewpoint - The company has approved the 2025 equity incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and core team members for long-term development [1][17]. Group 1: Equity Incentive Plan - The company held its third board meeting and third supervisory board meeting on June 6, 2025, where the 2025 equity incentive plan draft was approved [1]. - The plan aims to establish a long-term incentive mechanism to motivate directors, senior management, and core employees [17]. - The plan was developed in accordance with relevant laws and regulations, ensuring compliance with the Company Law and Securities Law [17][19]. Group 2: Insider Information Management - The company implemented necessary confidentiality measures regarding the equity incentive plan and registered insiders [2][6]. - A self-inspection was conducted on the trading activities of insiders and incentive objects during the six months prior to the plan's disclosure [3][4]. - No insider trading or information leakage was found during the self-inspection period, confirming compliance with legal regulations [7][6]. Group 3: Shareholder Meeting - The first temporary shareholder meeting of 2025 was held on June 26, 2025, with a total of 126 shareholders participating, representing 26.0116% of the total shares [15]. - The meeting approved the equity incentive plan with 99.2302% of the votes in favor, indicating strong support from shareholders [17][20]. - The meeting also addressed the authorization of the board to manage the equity incentive plan, which received 99.2076% approval [22][24].

Core Viewpoint - Company Shanying International (600567.SH) is demonstrating confidence in the market by announcing a share buyback plan, aiming to enhance its stock price and support employee stock ownership plans [1][2]. Group 1: Share Buyback Announcement - Shanying International plans to repurchase shares using its own and self-raised funds through centralized bidding, with a total buyback amount between 5 billion and 10 billion yuan [1]. - The buyback price will not exceed 2.50 yuan per share, which is 35.87% higher than the current market price of 1.84 yuan per share [1]. Group 2: Financial Performance and Historical Context - Since its listing in 2001, Shanying International has experienced two years of losses, with a significant loss of 15 billion yuan in 2022 due to goodwill impairment from previous acquisitions [2]. - The company made high-premium acquisitions in 2017 and 2018, which initially boosted profits but later led to substantial losses when the acquired companies underperformed [2]. Group 3: Recent Operational Developments - In 2023 and 2024, Shanying International reported revenues of 293.3 billion yuan and 292.3 billion yuan, with net profits of 1.56 billion yuan and a loss of 4.51 billion yuan, respectively [3]. - The company is adjusting its overseas strategy and has seen a 6.71% increase in raw paper production to 7.24 million tons in 2024, with sales up by 8.03% to 7.32 million tons [3]. - As of the first quarter of 2025, Shanying International's total assets were 539.7 billion yuan, with a debt ratio of 68.76%, down from 71.37% the previous year [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、根据公司2021年股票期权与限制性股票激励计划的相关规定，对因离职而不具备激励对象资格的3名 激励对象所持有的尚未解除限售的限制性股票实施回购注销，涉及股份数量38,000股，占回购注销前公 司总股本的0.0088%。 2、截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公司办理完成本次部分限制性 股票的回购注销事宜。本次回购注销完成后，公司总股本由429,685,790股变更为429,647,790股。 重庆百亚卫生用品股份有限公司（以下简称"公司"）于2025年3月21日召开的第四届董事会第四次会议 和第四届监事会第四次会议，2025年4月11日召开的2024年年度股东大会分别审议通过了《关于回购注 销2021年股票期权与限制性股票激励计划部分限制性股票的议案》。具体内容详见公司于2025年3月22 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回购注销2021年股票期权与限制性股票激励计划 部分限制性股票的公告》 ...

自董事会审议利润分配预案后至实施利润分配方案的股权登记日期间，若公司总股本 因股权激励行权、股份回购等原因发生变动的，依照未来实施分配方案时股权登记日的总 股本为基数实施，并保持上述分配比例不变对总额进行调整。 二、本次权益分派方案 证券代码：002230 证券简称：科大讯飞 公告编号：2025-023 科大讯飞股份有限公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： （2023 年修订）等相关规定，上市公司回购专用账户中的股份不享有利润分配等权利。科 大讯飞股份有限公司（下称"公司"） 回购专用证券账户上的 8,394,061 股股份不参与本 次权益分派，以公司现有总股本（2,311,692,581 股）剔除已回购股份（8,394,061 股）后的 司 本 次 实 际 现 金 分 红 的 总 额 = 实 际 参 与 权 派 的 股 本 × 比 例 ， 即 ： 230,329,852.00 元 =2,303,298,520 股×0.10 元/股。因公司回购股份不参与分红，本次权益分派实施后，根据 股票市值不变原则，实施权益分派前后公司总股本保持 ...